PCN2I A PHARMACOECONOMIC MODEL OF THE COST-EFFECTIVENESS OF GEFITINIB ('IRESSA') COMPARED WITH BEST SUPPORTIVE CARE (BSC) IN THIRD-LINE TREATMENT OF PATIENTS WITH REFRACTORY ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) IN THE UK
Nov 1, 2004, 00:00 AM
10.1016/S1098-3015(10)65755-5
https://www.valueinhealthjournal.com/article/S1098-3015(10)65755-5/fulltext
Section Title :
Section Order :
121
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65755-5&doi=10.1016/S1098-3015(10)65755-5